Related Experiment Video
Updated: Jun 12, 2026

A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes
Published on: February 17, 2023
Antihyperglycemic effect of protocatechuic acid on streptozotocin-diabetic rats
Ranganathan Harini1, Kodukkur Viswanathan Pugalendi
1Department of Biochemistry and Biotechnology, Faculty of Science, Annamalai University, Annamalainagar - 608 002, Tamilnadu, India.
Abstract:
Protocatechuic acid (PCA) (3,4-dihydroxybenzoic acid), a natural phenolic compound found in many edible and medicinal plants, is a major benzoic acid derivative with a strong antioxidative effect, 10-fold higher than that of alpha-tocopherol. The present study is aimed at evaluating the antidiabetic effect of PCA on STZ-diabetic rats. Diabetes was induced in male albino Wistar rats by the administration of STZ (40 mg/kg BW, i.p.). PCA was administered orally at three different doses (50, 100, 200 mg/kg BW/day) to STZ-diabetic rats for 45 days. Diabetic rats showed increase in plasma glucose and glycosylated hemoglobin (HbA1c) and a decrease in plasma insulin and hemoglobin (Hb). The activities of gluconeogenic enzymes like glucose 6-phosphatase and fructose 1,6-bisphosphatase increased whereas the glycolytic enzyme glucokinase decreased in the liver along with glycogen content. The oral administration of PCA or glibenclamide in saline, for 45 days, prevented the changes and improved toward normalcy. No significant effect was observed in normal rats treated with PCA. Thus, our results show that PCA at 100 mg possesses a potential antihyperglycemic effect that is comparable with glibenclamide.
Related Concept Videos
Dipeptidyl Peptidase 4 Inhibitors
Oral Hypoglycemic Agents: Biguanides and Glitazones
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are typically...
Oral Hypoglycemic Agents: Glinides
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Type II Diabetes II: Pathophysiology
